nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alone, lonely, and missed
|
Kahn, James |
|
|
9 |
6 |
p. 565-566 |
artikel |
2 |
A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19
|
McGonagle, Dennis |
|
|
9 |
6 |
p. 665-672 |
artikel |
3 |
Challenges and opportunities to end tuberculosis in the COVID-19 era
|
Wingfield, Tom |
|
|
9 |
6 |
p. 556-558 |
artikel |
4 |
Correction to Lancet Respir Med 2021; published online April 9. https://doi. org/10.1016/S2213-2600(21)00160-0
|
|
|
|
9 |
6 |
p. e55 |
artikel |
5 |
Correction to Lancet Respir Med 2021; published online April 19. https://doi.org/10.1016/S2213-2600(21)00096-5
|
|
|
|
9 |
6 |
p. e55 |
artikel |
6 |
Correction to Lancet Respir Med 2021; published online April 9. https://doi. org/10.1016/S2213-2600(21)00171-5
|
|
|
|
9 |
6 |
p. e55 |
artikel |
7 |
Correction to Lancet Respir Med 2021; published online Feb 26. https://doi.org/10.1016/S2213-2600(20)30448-3
|
|
|
|
9 |
6 |
p. e55 |
artikel |
8 |
COVID-19 pathophysiology: looking beyond acute disease
|
The Lancet Respiratory Medicine, |
|
|
9 |
6 |
p. 545 |
artikel |
9 |
COVID-19 survivor experiencing long-term symptoms
|
Kirby, Tony |
|
|
9 |
6 |
p. 570-572 |
artikel |
10 |
Desperation in the time of COVID-19
|
Adhikari, Biplov |
|
|
9 |
6 |
p. 567-569 |
artikel |
11 |
Development of new antibacterial agents: a sense of urgency needed
|
Burki, Talha Khan |
|
|
9 |
6 |
p. e54 |
artikel |
12 |
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
|
Shostak, Yael |
|
|
9 |
6 |
p. e52-e53 |
artikel |
13 |
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
|
Yap, Timothy A |
|
|
9 |
6 |
p. 613-621 |
artikel |
14 |
Evidence-based European guidelines for the diagnosis of asthma in children aged 5–16 years
|
Gaillard, Erol A |
|
|
9 |
6 |
p. 558-560 |
artikel |
15 |
From female warriors in the rainforest to infectious disease specialists: COVID-19 in the Amazon
|
Safe, Izabella |
|
|
9 |
6 |
p. 566-567 |
artikel |
16 |
Has the time come to end use of the blue inhaler?
|
Bush, Andrew |
|
|
9 |
6 |
p. e51 |
artikel |
17 |
High COVID-19 death rates in prisons in England and Wales, and the need for early vaccination
|
Braithwaite, Isobel |
|
|
9 |
6 |
p. 569-570 |
artikel |
18 |
Immunotherapy in COVID-19: why, who, and when?
|
Sinha, Pratik |
|
|
9 |
6 |
p. 549-551 |
artikel |
19 |
Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice
|
Khanna, Dinesh |
|
|
9 |
6 |
p. 560-562 |
artikel |
20 |
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
|
McElvaney, Oliver J |
|
|
9 |
6 |
p. 643-654 |
artikel |
21 |
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
|
Angriman, Federico |
|
|
9 |
6 |
p. 655-664 |
artikel |
22 |
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study
|
Combs, Michael P |
|
|
9 |
6 |
p. 601-612 |
artikel |
23 |
New and old treatments for malignant mesothelioma: not just immunotherapy
|
Nowak, Anna K |
|
|
9 |
6 |
p. 547-549 |
artikel |
24 |
Non-invasive respiratory support strategies in COVID-19
|
Gorman, Ellen |
|
|
9 |
6 |
p. 553-556 |
artikel |
25 |
REPLACE and the role of riociguat in pulmonary arterial hypertension therapy
|
Frantz, Robert P |
|
|
9 |
6 |
p. 546-547 |
artikel |
26 |
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
|
Fennell, Dean A |
|
|
9 |
6 |
p. 593-600 |
artikel |
27 |
Saliva as a gold-standard sample for SARS-CoV-2 detection
|
Tan, Steph H |
|
|
9 |
6 |
p. 562-564 |
artikel |
28 |
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
|
Hoeper, Marius M |
|
|
9 |
6 |
p. 573-584 |
artikel |
29 |
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
|
de Gooijer, Cornedine J |
|
|
9 |
6 |
p. 585-592 |
artikel |
30 |
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
|
Osuchowski, Marcin F |
|
|
9 |
6 |
p. 622-642 |
artikel |
31 |
Vascular mechanisms and manifestations of COVID-19
|
Levi, Marcel |
|
|
9 |
6 |
p. 551-553 |
artikel |